BIOLOGICAL PREPARATIONS DERIVED FROM MAMMALIAN

Brand Owner (click to sort) Address Description
ORTHOSTEM Wasielewski, Ray 1275 Kinnear Road Columbus OH 43212 Biological preparations derived from mammalian molars for use in transplantation surgery and therapy for tissue injury or degeneration;
PULPCYTE VETGRAFT 1275 KINNEAR ROAD COLUMBUS OH 45212 Biological preparations derived from mammalian molars for use in transplantation surgery and therapy for tissue injury or degeneration;PULP CYTE;
PULPCYTE DENTAL STEM CELL DEVELOPMENT COMPANY, LTD. 1275 KINNEAR ROAD COLUMBUS OH 43212 Biological preparations derived from mammalian molars for use in transplantation surgery and therapy for tissue injury or degeneration;PULP CYTE;
VETGRAFT Wasielewski, Ray 1275 Kinnear Road Columbus OH 43212 Biological preparations derived from mammalian molars for use in transplantation surgery and therapy for tissue injury or degeneration;VET GRAFT;
VETGRAFT Ray Wasielewski 7590 Brandon Road New Albany OH 43054 Biological preparations derived from mammalian molars for use in transplantation surgery and therapy for tissue injury or degeneration;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Polynucleotides encoding mammalian ECM signaling molecules affecting the cell adhesion, migration, and proliferation activities characterizing such complex biological processes as angiogenesis, chondrogenesis, and oncogenesis, are provided. The polynucleotide compositions include DNAs and RNAs comprising part, or all, of an ECM signaling molecule coding sequence, or biological equivalents. Polypeptide compositions are also provided. The polypeptide compositions comprise mammalian ECM signaling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signaling molecules, and antibody products recognizing Cyr61. Also provided are methods for producing mammalian ECM signaling molecules. Further provided are methods for using mammalian ECM signaling molecules to screen for, and/or modulate, disorders associated with angiogenesis, chondrogenesis, and oncogenesis; ex vivo methods for using mammalian ECM signaling molecules to prepare blood products are also provided.